已收盤 07-02 16:00:00 美东时间
+1.230
+1.44%
2026年6月29日,生物制药公司Cytokinetics(股票代码:CYTK)披露最新内幕增减持动态,公司执行副总裁兼首席财务官李成完成两笔股票出售交易,合计...
06-30 14:23
今日重点评级关注:Evercore ISI集团:维持ProQR Therapeutics"跑赢大市"评级,目标价从5美元升至6美元;摩根士丹利:维持霍尼韦尔"标配"评级,目标价从245美元升至490美元
06-30 10:14
瑞银分析师阿什瓦尼·维尔马将Cytokinetics的评级从“中性”上调至“买入”,同时将其目标价从69美元上调至115美元。 译文内容由第三方软件翻译。 声明...
06-30 00:26
今日重点评级关注:Jones Trading:维持Definium Therapeutics"买入"评级,目标价从61美元升至74美元;韦德布什:维持Cerebras Systems"跑赢大市"评级,目标价从270美元升至280美元
06-25 11:32
瑞穗证券将纳斯达克上市生物制药公司Cytokinetics(CYTK)的股票目标价从100美元上调至118美元,维持“跑赢大盘”评级。 当前该股交易价为62....
06-24 21:26
Mizuho analyst Salim Syed maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $100 to $118.
06-24 21:04
今日重点评级关注:Chardan Capital:维持SAB Biotherapeutics"买入"评级,目标价从14美元升至16美元;Northland Capital Markets:维持Applied Digital"跑赢大市"评级,目标价从56美元升至82美元
06-18 19:08
Cytokinetics granted stock options, RSUs, and PSUs to 12 new employees as inducements to employment. The RSUs vest over 3 years, the stock options vest over 4 years with a $71.38 exercise price, and the PSUs are subject to performance goals. The company focuses on developing cardiovascular therapies, including MYQORZO® for hypertrophic cardiomyopathy and investigational drugs for heart failure.
06-17 20:00
Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $102 price target.
06-17 16:48
European Launch Follows Strong U.S. StartSOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the first commercial European launch
06-01 19:38